A recent study from Duan et al. investigating the use of such a therapeutic in a streptozotocin model of type-1 diabetes (T1D) demonstrated the ability of a probiotic transformed to express the full-length, inactive form of GLP-1 (1–37) to restore one third of the host insulin production20. The gene discussed is INS; the disease is type 1 diabetes mellitus.